{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T15:31:40Z","timestamp":1782833500767,"version":"3.54.5"},"update-to":[{"DOI":"10.12688\/f1000research.146982.1","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000}}],"reference-count":36,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns3:p>Backgrounds Venous Thromboembolism (VTE) is a disease entity comprising Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). VTE events increase the mortality rate of patients with cancer receiving platinum-based chemotherapy. Soluble P-Selectin, Neutrophil Extracellular Traps (NET), and myeloperoxidase (MPO) are risk factors associated with DVT in malignancy patients receiving platinum-based chemotherapy. The purpose of this study was to determine the role of soluble P-selectin, NET, and MPO as risk factors for DVT in patients with malignancy receiving platinum-based chemotherapy. Patients and Methods This study used a case-control design (matched pair case-control study) based on age and gender. The case group consisted of subjects with DVT, whereas the control group consisted of subjects without DVT. The subjects were 31 in each case and control groups. Soluble P-selectin, NET, and MPO levels were measured in each group. Results The mean age of case group was 50.26\u00b112.15 years meanwhile in control group was 52.81\u00b111.64 years. In the case group, 71% of the subjects were female, whereas 51.6% of the control group were male. Most subjects, either in the case group (71%) or the control group (71%), used carboplatin. In the case group, cervix malignancy was the most common malignancy (32.3%), whereas in the control group, it was nasopharyngeal malignancy (25.8%). High soluble P-selectin level was a risk factor for DVT (OR 3.38, CI 1.180 \u2013 9.780, p=0.02). A high NET level was also a risk factor for DVT (OR 2.88, CI 1.026-8.074, p=0.04). The high MPO levels in this study could not be proven as a risk factor. Conclusions Soluble P-selectin and NET are risk factors that play a role in the pathophysiology of DVT through the pathomechanism of immunothrombosis induced by endothelial injury and activation of monocytes and neutrophils due to the use of platinum-based chemotherapy.<\/ns3:p>","DOI":"10.12688\/f1000research.146982.2","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T14:55:08Z","timestamp":1752764108000},"page":"427","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["High Levels of Soluble P-selectin, Neutrophil Extracellular Traps, and Myeloperoxidase as Risk Factor of Deep Vein Thrombosis in Malignancy Patients Receiving Platinum-Based Chemotherapy"],"prefix":"10.12688","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8763-6631","authenticated-orcid":false,"given":"Ni Made Renny Anggreni","family":"Rena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I Made","family":"Bakta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketut","family":"Suega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"ref2","first-page":"14-24","article-title":"IDENTIA registry: incidence of deep vein thrombosis in medically ill subjects at high risk in Indonesia: a prospective study.","volume":"52","author":"K Tambunan","year":"2020","journal-title":"Acta Med. Indones."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3390\/cancers10100380","article-title":"Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment.","volume":"10","author":"N Abdol-Razak","year":"2018","journal-title":"Cancers (Basel)."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3390\/cancers11010095","article-title":"Predicting VTE in cancer patients: candidate biomarkers and risk assessment models.","volume":"11","author":"S Riondino","year":"2019","journal-title":"Cancers (Basel)."},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1-11","DOI":"10.1183\/16000617.0119-2018","article-title":"Cancer-associated thrombosis: the when, how and why.","volume":"28","author":"C Fernandes","year":"2019","journal-title":"Eur. Respir. Rev."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"5-10","DOI":"10.1177\/1073274805012003S02","article-title":"Cancer and Venous Thromboembolism: Scope and The Problem.","volume":"12","author":"J Heit","year":"2005","journal-title":"Cancer Control."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"464-474","DOI":"10.1038\/nrcardio.2015.83","article-title":"Epidemiology of venous thromboembolism.","volume":"12","author":"J Heit","year":"2015","journal-title":"Nat. Rev. Cardiol."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"555-568","DOI":"10.1016\/j.thromres.2005.10.015","article-title":"Chemotherapy-induced thrombosis.","volume":"118","author":"T Haddad","year":"2006","journal-title":"Thromb. Res."},{"key":"ref9","first-page":"471-476","article-title":"Understanding and improving platinum anticancer drugs\u2013phenanthriplatin.","volume":"34","author":"T Johnstone","year":"2014","journal-title":"Anticancer Res."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"927-929","DOI":"10.1097\/CAD.0b013e3283100e9c","article-title":"Cisplatin-associated thrombosis.","volume":"19","author":"M Jafri","year":"2008","journal-title":"Anti-Cancer Drugs."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"17-24","DOI":"10.1016\/j.thromres.2013.08.014","article-title":"The role of soluble P selectin in the diagnosis of venous thromboembolism.","volume":"133","author":"C Antonopoulos","year":"2014","journal-title":"Thromb. Res."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"508-518","DOI":"10.1111\/jth.13951","article-title":"Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients.","volume":"16","author":"L Mauracher","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"459-471","DOI":"10.1007\/s11239-010-0460-x","article-title":"Biochemical markers for the diagnosis of venous thromboembolism: the past, present and future.","volume":"30","author":"G Lippi","year":"2010","journal-title":"J. Thromb. Thrombolysis."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2703-2708","DOI":"10.1182\/blood-2008-02-142422","article-title":"High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS).","volume":"112","author":"C Ay","year":"2008","journal-title":"Blood, The Journal of the American Society of Hematology."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e22946","DOI":"10.4161\/onci.22946","article-title":"Neutrophil extracellular traps: A new link to cancer-associated thrombosis and potential implications for tumor progression.","volume":"2","author":"M Demers","year":"2013","journal-title":"Oncoimmunology."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e018910-e018916","DOI":"10.1136\/bmjopen-2017-018910","article-title":"Venous thromboembolism in patients with cancer: Design and rationale of a multicentre, prospective registry (Cancer-VTE Registry).","volume":"8","author":"Y Ohashi","year":"2018","journal-title":"BMJ Open."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"166-171","DOI":"10.1016\/j.thromres.2018.09.056","article-title":"Impact of sex, age, and risk factors for venous thromboembolism on the initial presentation of first isolated symptomatic acute deep vein thrombosis.","volume":"173","author":"S Barco","year":"2019","journal-title":"Thromb. Res."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"349-357","DOI":"10.6004\/jnccn.2013.0154","article-title":"Association between cancer types, cancer treatments and venous thromboembolism in medical oncology patients.","volume":"11","author":"B Streiff","year":"2013","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12885-016-3032-4","article-title":"Incidence of venous thromboembolism in cancer patients treated with cisplatin based chemotherapy - a cohort study.","volume":"17","author":"M Zahir","year":"2017","journal-title":"BMC Cancer."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12959-020-00247-6","article-title":"Von Willebrand factor: antigen and ADAMTS-13 level, but not soluble P-selectin, are risk factors for the first asymptomatic deep vein thrombosis in cancer patients undergoing chemotherapy.","volume":"18","author":"B Setiawan","year":"2020","journal-title":"Thromb. J."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.3390\/ijms21061920","article-title":"From classical laboratory parameters to novel biomarkers for the diagnosis of venous thrombosis.","volume":"21","author":"L Anghel","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1529-1538","DOI":"10.12816\/0044679","article-title":"Soluble p-selectin level in patients with deep venous thrombosis.","volume":"70","author":"A Saadeldin","year":"2018","journal-title":"Egypt J. Hosp. Med."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"34-45","DOI":"10.1038\/nri3345","article-title":"Thrombosis as an intravascular effector of innate immunity.","volume":"13","author":"B Engelmann","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1777-1783","DOI":"10.1161\/ATVBAHA.111.242859","article-title":"Neutrophil extracellular trap (NET) impact on deep vein thrombosis.","volume":"32","author":"T Fuchs","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1-17","DOI":"10.1371\/journal.pone.0191231","article-title":"Citrullinated histone H3 as a novel prognostic blood marker in patients with advanced cancer.","volume":"13","author":"C Th\u00e5lin","year":"2018","journal-title":"PLoS One."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"311-320","DOI":"10.1111\/bjh.15906","article-title":"Citrullinated histone H3, a biomarker for neutrophil extracellular trap formation, predicts the risk of mortality in patients with cancer.","volume":"186","author":"E Grilz","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"341-348.e1","DOI":"10.1016\/j.jvsv.2012.12.002","article-title":"Plasma DNA is elevated in patients with deep vein thrombosis.","volume":"1","author":"J Diaz","year":"2013","journal-title":"J. Vasc. Surg. Venous Lymphat. Disord."},{"key":"ref26","first-page":"1-9","article-title":"Neutrophil extracellular traps and endothelial dysfunction in atherosclerosis and thrombosis.","volume":"8","author":"H Qi","year":"2017","journal-title":"Front. Immunol."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"910795","DOI":"10.3389\/fmolb.2022.910795","article-title":"Hemoglobin can Act as a (Pseudo)-Peroxidase in Vivo. What is the Evidence?","volume":"9","author":"A Alayash","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/medsci6020033","article-title":"Myeloperoxidase as an active disease biomarker: recent biochemical and pathological perspectives.","volume":"6","author":"A Khan","year":"2018","journal-title":"Med. Sci."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"4243","DOI":"10.3390\/cancers13164243","article-title":"Adhesion of platelets to colon cancer cells is necessary to promote tumor development in xenograft, genetic and inflammation models.","volume":"13","author":"M Cariello","year":"2021","journal-title":"Cancers."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"29202-29210","DOI":"10.1074\/jbc.m312951200","article-title":"Modified heparin inhibits P-selectin-mediated cell adhesion of human colon carcinoma cells to immobilized platelets under dynamic flow conditions.","volume":"279","author":"M Wei","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-428497\/v1","article-title":"Soluble P-selectin and correlation with Prothrombin Fragment 1+ 2 in myeloid malignancies in Cipto Mangunkusumo general hospital.","volume":"19","author":"L Sukrisman","year":"2021","journal-title":"Thromb. J."},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.6084\/m9.figshare.25398304.v1","author":"N Rena","year":"2024","journal-title":"figshare."},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.6084\/m9.figshare.25398298.v1","article-title":"Informed Consent.docx. figshare.","author":"N Rena","year":"2024","journal-title":"Journal contribution."},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.6084\/m9.figshare.25398301.v1","article-title":"Data Collection Form.doc. figshare.","author":"N Rena","year":"2024","journal-title":"Journal contribution."},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.6084\/m9.figshare.25398307.v1","article-title":"PROCEDURE AND METHODS (1).doc. figshare.","author":"N Rena","year":"2024","journal-title":"Journal contribution."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/13-427\/v2\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/13-427\/v2\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/13-427\/v2\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T14:55:09Z","timestamp":1752764109000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/13-427\/v2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":36,"URL":"https:\/\/doi.org\/10.12688\/f1000research.146982.2","relation":{"has-version":[{"id-type":"doi","id":"10.12688\/f1000research.146982.1","asserted-by":"subject"}],"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.183975.r398935","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.183975.r398936","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.183975.r398937","asserted-by":"object"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/13-427\/v2#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.161114.r296985, Eko Adhi Pangarsa, Diponegoro University, Dr. Kariadi General Hospital, Semarang, 18 Jul 2024, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/13-427\/v1#referee-response-296985","order":0,"name":"referee-response-296985","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.161114.r320045, Irawan Cosphiadi, Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo National General Hospital, Universitas Indonesia, Jakarta, 22 Nov 2024, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/13-427\/v1#referee-response-320045","order":1,"name":"referee-response-320045","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.161114.r276428, Shinta Wardani, Division of Hematology and Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, 13 Jan 2025, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/13-427\/v1#referee-response-276428","order":2,"name":"referee-response-276428","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":3,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}